Nonsteroidal <scp>Anti‐inflammatory</scp> Use and <scp><i>LRRK2</i></scp> Parkinson's Disease Penetrance
Marta San Luciano(University of California, San Francisco), Rachel Saunders‐Pullman(Mount Sinai Beth Israel), Kathrin Brockmann(Oregon Health & Science University), Jean‐Christophe Corvol(Centre National de la Recherche Scientifique), George D. Mellick(Griffith University), Susan Bressman(Icahn School of Medicine at Mount Sinai), Christine Klein(University of Lübeck), Alexis Brice(Inserm), Samuel M. Goldman(University of California, San Francisco), Mériem Tazir(Hôpital Mustapha Pacha), Carolyn M. Sue(UNSW Sydney), Simone Brockman(The University of Western Australia), Stefano Goldwurm(Istituto Ortopedico Gaetano Pini), Connie Marras(University of Toronto), Eduardo Tolosa(Biomedical Research Networking Center on Neurodegenerative Diseases), Caroline M. Tanner(University of California, San Francisco), Cheryl Meng(University of California, San Francisco), Eng King Tan(Singapore General Hospital), Joachim J. Ferreira(National Legal Medicine Institute), Kazuko Hasegawa(National Sagamihara Hospital), J. William Langston(St. Jude Children's Research Hospital), Anthony E. Lang(University of Toronto), Birgitt Schüle(Stanford University), Daniela Berg(Christian-Albrechts-Universität zu Kiel)
Cited by 87
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k